NASDAQ:SLGLSol Gel Technologies Stock Price, Forecast & News

Sol Gel Technologies' stock was trading at $8.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLGL shares have increased by 1.0% and is now trading at $8.33. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sol Gel Technologies.

Sol Gel Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Sol Gel Technologies.

Sol Gel Technologies Ltd (NASDAQ:SLGL) posted its earnings results on Thursday, May, 14th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05. The company earned $3.47 million during the quarter, compared to analysts' expectations of $3.37 million. Sol Gel Technologies had a negative return on equity of 44.64% and a negative net margin of 129.88%. View Sol Gel Technologies' earnings history.

4 Wall Street analysts have issued 1-year price targets for Sol Gel Technologies' stock. Their forecasts range from $21.00 to $33.00. On average, they anticipate Sol Gel Technologies' stock price to reach $25.25 in the next year. This suggests a possible upside of 203.1% from the stock's current price. View analysts' price targets for Sol Gel Technologies.

Media coverage about SLGL stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sol Gel Technologies earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutSol Gel Technologies.

Sol Gel Technologies saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 53,400 shares, a decline of 18.8% from the April 30th total of 65,800 shares. Based on an average daily trading volume, of 65,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.7% of the shares of the company are sold short. View Sol Gel Technologies' Current Options Chain.

Some companies that are related to Sol Gel Technologies include Sinovac Biotech (SVA), INDIVIOR PLC/S (INVVY), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), DiaMedica Therapeutics (DMCAF), Passage Bio (KROS), Ardelyx (ARDX), Trillium Therapeutics (TRIL), Syndax Pharmaceuticals (SNDX), Dynavax Technologies (DVAX), Frequency Therapeutics (FREQ), Radius Health (RDUS), Aprea Therapeutics (APRE), Athersys (ATHX) and Urogen Pharma (URGN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol Gel Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Tesla (TSLA), Advanced Micro Devices (AMD), eHealth (EHTH), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA), Micron Technology (MU) and NeoPhotonics (NPTN).

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Sol Gel Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Phoenix Holdings Ltd. (13.25%), Ion Asset Management Ltd. (1.24%), Invesco Ltd. (0.39%), Raymond James Financial Services Advisors Inc. (0.22%), Raymond James & Associates (0.20%) and Morgan Stanley (0.09%).

SLGL stock was acquired by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Ion Asset Management Ltd., Invesco Ltd., Two Sigma Investments LP, Morgan Stanley, Raymond James Financial Services Advisors Inc., Raymond James & Associates, and Steward Partners Investment Advisory LLC.

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SLGL stock can currently be purchased for approximately $8.33.

Sol Gel Technologies has a market capitalization of $169.85 million and generates $22.90 million in revenue each year. The company earns $-24,610,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

The official website for Sol Gel Technologies is www.sol-gel.com.

Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company can be reached via phone at 972-8931-3429 or via email at [email protected]